Harbour BioMed, a Shanghai-based biotechnology company focusing on cancer screening, today announced completion of its US$102.8 Million series C round financing to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
